Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SNT-101 (Sonata Therapeutics)
- Development stage
- Preclinical
- Lead developer
- Sonata Therapeutics
- Modality
- Small Molecules
01
Overview
SNT-101 (also known as SNT-4288 or compound 101) is a proprietary small molecule ferroptosis inducer being developed by Sonata Therapeutics. It is designed to target and eliminate cancer cells by triggering ferroptosis, an iron-dependent form of regulated cell death characterized by the accumulation of lipid peroxides and oxidative stress. SNT-101 has demonstrated preclinical efficacy in non-small cell lung cancer (NSCLC) cell lines, including those with EGFR mutations and resistance to EGFR inhibitors, as well as in sarcoma models (such as fibrosarcoma and rhabdomyosarcoma), where it induces lipid peroxidation and immunogenic cell death.
- Other names
- proprietary ferroptosis inducer
02
Targets
GPX4 (Glutathione peroxidase 4)
Beyond the preview
Go deeper on SNT-101 (Sonata Therapeutics).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SNT-101 (Sonata Therapeutics).